Preclinical Evaluation of a Novel Polymer-free Everolimus-eluting Stent in a Mid-term Porcine Coronary Restenosis Model

Kyung Hoon Cho,1 Myung Ho Jeong,1,2 Dae Sung Park,3 Moonki Kim,2 JungHa Kim,2 Jun-Kyu Park,4 Xiongyi Han,1 Dae Young Hyun,1 Min Chul Kim,1,2 Doo Sun Sim,1,2 Young Joon Hong,1,2 Jun Han Kim,1,2 and Youngkeun Ahn1,2

1Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea
2Department of Cardiology, Chonnam National University Medical School, Hwasun, Korea
3Cardiovascular Research Center, Chonnam National University Hospital, Gwangju, Korea
4CGBio Co. Ltd., Seoul, Korea

ABSTRACT

Background: Titanium dioxide films exhibit good biocompatibility and may be effective as drug-binding matrices for drug-eluting stents. We conducted a mid-term evaluation of a novel polymer-free everolimus-eluting stent using nitrogen-doped titanium dioxide film deposition (TIGEREVOLUTION®) in comparison with a commercial durable polymer everolimus-eluting stent (XIENCE Alpine®) in a porcine coronary restenosis model.

Methods: Twenty-eight coronary arteries from 14 mini-pigs were randomly allocated to TIGEREVOLUTION® stent and XIENCE Alpine® stent groups. The stents were implanted in the coronary artery at a 1.1 – 1.2:1 stent-to-artery ratio. Eleven stented coronary arteries in each group were finally analyzed using coronary angiography, optical coherence tomography, and histopathologic evaluation 6 months after stenting.

Results: Quantitative coronary analysis showed no significant differences in the pre-procedural, post-procedural, and 6-month lumen diameters between the groups. In the volumetric analysis of optical coherence tomography at 6 months, no significant differences were observed in stent volume, lumen volume, and percent area stenosis between the groups. There were no significant differences in injury score, inflammation score, or fibrin score between the groups, although the fibrin score was zero in the TIGEREVOLUTION® stent group (0 vs. 0.07 ± 0.11, P = 0.180).

Conclusion: Preclinical evaluation, including optical coherence tomographic findings 6 months after stenting, demonstrated that the TIGEREVOLUTION® stent exhibited efficacy and safety comparable with the XIENCE Alpine® stent, supporting the need for further clinical studies on the TIGEREVOLUTION® stent.

Keywords: Drug-eluting Stents; Polymers; Swine; Titanium Dioxide; Optical Coherence Tomography
Polymer-Free Everolimus-Eluting Stents

MIN CHUL KIM
https://orcid.org/0000-0001-6026-7702
Doo Sun Sim
https://orcid.org/0000-0003-4162-7902
Young Joon Hong
https://orcid.org/0000-0003-0192-8761
Ju Han Kim
https://orcid.org/0000-0002-3186-0770
Young Keun Ahn
https://orcid.org/0000-0003-2022-9368

INTRODUCTION

Atherosclerotic coronary artery disease is one of the main causes of death worldwide. Since the first successful balloon angioplasty for coronary artery stenosis in 1977,1 percutaneous coronary intervention has come a long way in terms of interventional devices and technical aspects. Drug-eluting stents (DESs) reduce the rate of in-stent restenosis compared with bare metal stents (BMSs). However, the apparent increase in late stent thrombosis remains a major concern.2 The polymer used for drug coating onto a metallic alloy is associated with arterial inflammation and late stent thrombosis.3-5 Furthermore, polymer degradation and consequential fragmentation can cause serious adverse events, including arterial embolism.6,7

The authors previously developed a novel method to coat a drug onto a titanium dioxide (TiO2) film without a polymer to avoid the problems associated with polymer-based DES.8,9 Furthermore, a new polymer-free everolimus-eluting stent was developed using this technology, as well as a new BMS (TIGER®; CGBio, Seoul, Korea), named the TIGEREVOLUTION® stent (TIGER EverOlimus eULting stent using TiO2 thIN film; CGBio).10-12

In this study, we investigated the efficacy and safety of the TIGEREVOLUTION® stent in comparison with a commercial durable polymer-based DES (XIENCE Alpine®; Abbott Vascular, Santa Clara, CA, USA) using 6-month follow-up coronary angiography, quantitative coronary analysis (QCA), optical coherence tomography (OCT), and histopathological analysis in a porcine coronary restenosis model.

METHODS

Preparation of a TiO2 film-coated stent with everolimus (TIGEREVOLUTION®)

A new BMS with excellent mechanical performance (TIGER®) was designed using a cobalt-chromium-based alloy because it is stronger and more biocompatible than stainless steel.12 The cobalt-chromium tube was cut using a laser cutter (Rofin, Starcut, Hamburg, Germany), followed by ultrasonic cleaning with acetone, ethanol, and distilled water. The tube was then subjected to heat treatment and polishing. The plasma-enhanced chemical vapor deposition process was used to deposit TiO2 thin films onto the BMS. When the TiO2 thin film was deposited at a discharge power of 5 W, it showed a highly smooth surface with a surface roughness of 9.4 nm, mechanical stability, good adhesion, and blood compatibility. The TiO2 film was surface-modified with water plasma to introduce hydroxyl groups onto the TiO2 surface. Subsequently, everolimus (LC Laboratories, Woburn, MA, USA) was grafted to the abluminal surface through the formation of ester bonds between the hydroxyl groups of the modified TiO2 film and the carboxyl groups of everolimus. The “method for manufacturing of drug-releasing stent coated with titanium-oxide thin film” has been granted a United States patent (No. US 8,999,456 B2). The surface morphology of the stent with nitrogen-doped TiO2 film deposition was investigated using scanning electron microscopy, which demonstrated a homogenous coating, with no evidence of cracks after stent expansion.13 The configuration and structure of the stent strut before and after balloon inflation are illustrated in Fig. 1A-C. The stent strut and coating thickness of the TiO2 film were 70 µm and 50 nm, respectively (Fig. 1D).

Study protocol

The study animals were mini-pigs (Micropig® T-type male swine; Apures, Pyeongtaek, Korea) weighing between 15 and 20 kg. The exclusion criteria for the analysis included...
post-procedural complications such as major arterial dissection, which had the potential to affect the outcomes, and other major events that were judged to be relevant to the outcomes. Aspirin (100 mg) and clopidogrel (75 mg) were administered daily for 5 days before the procedure. On the day of the procedure, the pigs were anesthetized with zolazepam and tiletamine (2.5 mg/kg; Zoletil50; Virvac, Caros, France), xylazine (3 mg/kg, Rompun; Bayer AG, Leverkusen, Germany), and azaperone (6 mg/kg, Stresnil; Janssen-Cilag, Neuss, Germany). An oxygen mask was used to supply continuous oxygen. Continuous hemodynamic monitoring, including electrocardiography, was performed during the procedure. Left carotid artery cutdown was performed under local anesthesia, and a 6 French sheath was inserted. An intravenous bolus of 5000 U of heparin was administered, and the coronary artery was engaged using six French guiding catheters. Baseline coronary angiograms were obtained using a nonionic radiocontrast agent in two orthogonal views. Fourteen TIGEREVOLUTION® stents and 14 commercial everolimus-eluting stents (XIENCE Alpine®) were implanted in the coronary arteries of 14 mini-pigs. QCA (Caas Workstation; Pie Medical imaging B.V., Maastricht, the Netherlands) was performed to establish suitable coronary arterial locations amenable to stent implantation. Two different types of stents were implanted in one mini-pig. The stent was deployed by inflating the balloon with an intended stent-to-artery ratio of 1.1–1.2:1. Coronary angiography, QCA, and OCT were performed immediately after stenting. All pigs received aspirin 100 mg and clopidogrel 75 mg orally per day throughout the study period. Follow-up coronary angiography, QCA, OCT, and histopathological studies were performed 6 months after stenting. Pigs that had major arterial dissections on postprocedural OCT or died before 6 months were excluded. Ultimately, 11 mini-pigs were included in the final analysis. The study scheme is illustrated in Fig. 2. Assessments of QCA, OCT, and histopathologic findings were performed based on anatomical naming, and the analyzers were blinded. All stents were implanted at the Animal Laboratory of the Chonnam National University Hospital in the morning (9 AM to 12 AM) from September 2018 to November 2019.
OCT

OCT was performed using a 2.7 C7 Dragonfly Imaging Catheter (LightLab Imaging Inc., Westford, MA, USA). The catheter was placed in the native artery distal to the stented lesion. Automatic pullback at a speed of 20 mm/s was performed during continuous automatic flushing of iodixanol (Visipaque™, 320 mg I/L; GE Healthcare, Amersham, UK) at a rate of 2–5 mL/sec, using a Medrad injector (Medrad Inc., Warrendale, PA, USA). Qualitative and quantitative measurements were performed using OCT to assess the stented area immediately after stent implantation and at the 6-month follow-up. OCT images were analyzed at 1-mm longitudinal intervals in a blinded fashion. Volumetric analysis was performed to measure the stent area, lumen area, and neointimal hyperplasia area. Area stenosis was defined as the average area of stenosis in the entire stent.

Histopathologic analysis

The specimens were embedded, and sections of 10–20-µm thickness were obtained at a distance of approximately 1 mm. Then, these were stained using hematoxylin and eosin and Carstairs’ method. Histopathologic measurements were performed using a calibrated microscope, digital video imaging system, and microcomputer program (Visus 2000 Visual Image Analysis System, IMT Tech, CA, USA). The measurements were made on five cross-sections from the proximal and distal ends and three midpoints of each stented segment. Scores for injury, inflammation, and fibrin were calculated as previously described. Immunohistochemical analysis was performed to identify cluster of differentiation 31 (CD31)-positive cell expression, a marker of endothelialization. Non-specific reactivity was blocked using 3% fetal bovine serum in phosphate-buffered saline for 60 minutes. Immunohistochemistry was performed using a polyclonal anti-CD31 antibody (1:100; Abcam, Cambridge, MA, USA). Streptavidin Alexa Fluor® 488-conjugated anti-rabbit
immunoglobulin G (1:1,000; Invitrogen, St. Louis, MO, USA) was used as the secondary antibody for fluorescence microscopy. Images were captured using a Nikon Eclipse 80i fluorescence microscope (Nikon, Tokyo, Japan).

Statistical analysis
Data were presented as mean ± standard deviation. Unpaired Student’s t-test was used to compare the values between the stent groups. Statistical significance was set at $P < 0.05$. Statistical analysis was performed using R software (version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria).

Ethics statement
The study protocol and procedures for the care of the animals were approved by the Institutional Animal Care and Use Committee of Chonnam National University Hospital (approval no. CNU-IACUC-H-2018-5). The animal study conformed to the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and the ARRIVE Guidelines for Reporting Animal Research.

RESULTS

Drug release kinetics
The grafted quantity of everolimus was measured (Supplementary Method). This was followed by an in vivo drug release test as described previously.$^8$,$^9$,$^{13}$ The release rate of everolimus was lower in the electrospinning coating groups (25.2% ± 11.4% and 19.2% ± 15.0% in the TiO$_2$ and poly(lactic-co-glycolic acid) (PLGA) groups, respectively) on day 1 of incubation compared with the simple dip coating group (75.1% ± 11.4%) ($P < 0.001$) (Fig. 3). Everolimus was released continuously over a 4-week period, with a higher release rate within the first 7 days in the TiO$_2$ groups (96.4% ± 16.4% and 85.2% ± 14.6% in the simple dip coating and electrospinning group, respectively) than in the PLGA group (58.2% ± 17.6%).

Fig. 3. In vitro cumulative release kinetics of everolimus from the stent. The indicated values are the mean ± standard deviation (n = 10).

$^{10}$TiO$_2$ = titanium dioxide, PLGA = poly(lactic-co-glycolic acid).
Reprinted from Int J Cardiol 2016;222:436-440 with permission from Elsevier.
Coronary angiography and QCA

The total number of implanted stents was 28. From these, 22 stents were included in the final analysis (Fig. 2). The stented arteries were patent in both groups immediately after stent implantation and at the 6-month follow-up (Fig. 4A-H). Periprocedural QCA showed no significant difference in the lumen diameter between the groups (preprocedural, \(2.66 \pm 0.20\) mm in the TIGEREVOLUTION® stent vs. \(2.62 \pm 0.20\) mm in the XIENCE Alpine® stent, \(P = 0.983\); postprocedural, \(2.87 \pm 0.15\) vs. \(2.94 \pm 0.16\) mm, respectively; \(P = 0.367\)). There was also no significant difference in the lumen diameter at 6 months between the groups (2.49 \(\pm 0.17\) mm in the TIGEREVOLUTION® stent vs. 2.35 \(\pm 0.31\) mm in the XIENCE Alpine® stent; \(P = 0.199\)) (Table 1).

OCT

OCT was performed immediately after stent implantation and revealed no significant malappositions or fractures of the stents (Fig. 4I and K). The OCT findings at 6 months demonstrated no dismantling of the stents or thrombi in the stented arteries. The images

![Coronary angiography and OCT images](https://jkms.org)

**Fig. 4.** Efficacy of the TIGEREVOLUTION® stent. Coronary angiographic images of the TIGEREVOLUTION® stent (A) pre-implantation, (B) during implantation, (C) post-implantation, and (D) at the 6-month follow-up. Coronary angiographic images of the XIENCE Alpine® stent (E) pre-implantation, (F) during implantation, (G) post-implantation, and (H) at the 6-month follow-up. OCT images of the TIGEREVOLUTION® stent (I) post-implantation and (J) at the 6-month follow-up. OCT images of the XIENCE Alpine® stent (K) post-implantation and (L) at the 6-month follow-up. Volumetric analysis of the OCT images at the 6-month follow-up: (M) stent volume, (N) lumen volume, and (O) percentage area stenosis. The box displays the median value with an interquartile range. The black points represent mean values. OCT = optical coherence tomographic.
revealed a homogeneous intra-stent area, suggesting neointimal hyperplasia (Fig. 4J and L). In volumetric analysis of OCT, there was no significant difference in stent volume, lumen volume, and neointimal volume (stent volume, 110.89 ± 16.55 mm$^3$ in the TIGEREVOLUTION® stent vs. 111.97 ± 21.54 mm$^3$ in the XIENCE Alpine® stent, $P = 0.896$; lumen volume, 80.99 ± 21.73 mm$^3$ vs. 77.46 ± 23.82 mm$^3$, respectively, $P = 0.720$; and neointimal volume, 29.90 ± 10.44 mm$^3$ vs. 34.52 ± 19.33 mm$^3$, respectively, $P = 0.494$). Furthermore, the percentage area of stenosis was not significantly different between the groups (27.95% ± 11.52% in the TIGEREVOLUTION® stent vs. 31.05% ± 16.23% in the XIENCE Alpine® stent, $P = 0.611$) (Table 1 and Fig. 4M-O).

Histopathologic analysis

Representative histological images are shown in Fig. 5A-F. There were no significant differences in the injury score and inflammation score between the groups (injury score, 1.44 ± 0.50 in the TIGEREVOLUTION® stent vs. 1.39 ± 0.63 in the XIENCE Alpine® stent, $P = 0.847$; inflammation score, 1.37 ± 0.60 vs. 1.32 ± 0.41, respectively, $P = 0.837$) (Table 1 and Fig. 5G and H). Although the fibrin score was not significantly different between the groups, it was zero in the TIGEREVOLUTION® stent (0 vs. 0.07 ± 0.11, $P = 0.180$) (Table 1 and Fig. 5I). The expression of CD31 was also not significantly different between the groups (97.8 ± 3.8 in the TIGEREVOLUTION® stent vs. 95.8 ± 5.8 in the XIENCE Alpine® stent, $P = 0.282$) (Fig. 6).

| Table 1. Quantitative coronary analysis, optical coherence tomography, and histologic analysis between the groups |
| --- |
| **Variables** | TIGEREVOLUTION® ($n = 11$) | XIENCE Alpine® ($n = 11$) | $P$ value |
| **Quantitative coronary analysis** | | | |
| Pre-procedural | | | |
| Maximum, mm | 2.94 ± 0.20 | 2.94 ± 0.26 | 0.985 |
| Minimum, mm | 2.36 ± 0.30 | 2.36 ± 0.29 | 0.989 |
| Mean, mm | 2.66 ± 0.20 | 2.62 ± 0.20 | 0.983 |
| Post-procedural | | | |
| Maximum, mm | 3.11 ± 0.15 | 3.18 ± 0.19 | 0.347 |
| Minimum, mm | 2.51 ± 0.23 | 2.60 ± 0.25 | 0.284 |
| Mean, mm | 2.87 ± 0.15 | 2.94 ± 0.16 | 0.367 |
| At 6 months | | | |
| Maximum, mm | 2.83 ± 0.24 | 2.80 ± 0.27 | 0.792 |
| Minimum, mm | 2.16 ± 0.22 | 1.89 ± 0.41 | 0.069 |
| Mean, mm | 2.49 ± 0.17 | 2.35 ± 0.31 | 0.199 |
| **Optical coherence tomography at 6 mon** | | | |
| Incomplete strut coverage | None | None | NA |
| Mean stent area, mm$^2$ | 6.16 ± 0.92 | 6.22 ± 1.20 | 0.896 |
| Stent volume, mm$^3$ | 110.89 ± 16.55 | 111.97 ± 21.54 | 0.896 |
| Mean lumen area, mm$^2$ | 4.50 ± 1.21 | 4.30 ± 1.32 | 0.720 |
| Lumen volume, mm$^3$ | 80.99 ± 21.73 | 77.46 ± 23.82 | 0.720 |
| Mean neointimal area, mm$^2$ | 1.66 ± 0.58 | 1.92 ± 1.07 | 0.494 |
| Neointimal volume, mm$^3$ | 29.90 ± 10.44 | 34.52 ± 19.33 | 0.494 |
| Area stenosis, % | 27.95 ± 11.52 | 31.05 ± 16.23 | 0.611 |
| **Histologic analysis at 6 mon** | | | |
| Injury score | 1.44 ± 0.50 | 1.39 ± 0.63 | 0.847 |
| Inflammation score | 1.37 ± 0.60 | 1.32 ± 0.41 | 0.837 |
| Fibrin score | 0 | 0.07 ± 0.11 | 0.180 |

Values are presented as the mean ± standard deviation.

Area stenosis = (stent volume - lumen volume)/stent volume × 100%.

NA = not applicable.
**DISCUSSION**

In the present study, we used a porcine coronary restenosis model to investigate the efficacy and safety of the TIGEREVOLUTION® stent in comparison with a commercial durable polymer-based DES (XIENCE Alpine®; Abbott Vascular). Using optical coherence tomographic and pathologic analysis, the TIGEREVOLUTION® stent showed comparable results with the XIENCE Alpine® stent at the 6-month follow-up. Although the fibrin score was not significantly different between the groups, it was zero in the TIGEREVOLUTION®
stent group. Moreover, immunohistochemical staining revealed that the expression of CD31 was not significantly different between the groups.

DES significantly reduces the rates of in-stent restenosis by inhibiting neointimal tissue proliferation compared with BMS. However, higher rates of late and very late stent thrombosis in DES remain the major disadvantages in practical use compared with BMS. Therefore, prolonged dual antiplatelet therapy is recommended to prevent stent thrombosis in patients receiving DES implantation unless there are contraindications such as excessive risk of bleeding. The polymer used for drug coating onto a metallic alloy provides controlled drug release, but it is also associated with hypersensitivity reactions and late stent thrombosis. Polymer-free DES may be a promising device-based strategy in a complex growing population of patients with a combined high bleeding risk and high thrombosis risk, owing to the possible shortened duration of dual antiplatelet therapy. Urban et al. recruited 2466 patients with high bleeding risk and randomized them to BMS or polymer-free DES (BioFreedom®, Biosensors Europe, Morges, Switzerland) groups under a dual antiplatelet duration of 1 month. At 390 days, the composite of cardiac death, myocardial infarction, or stent thrombosis occurred in 112 patients (9.4%) in the polymer-free DES group and in 154 patients (12.9%) in the BMS group (risk difference, 3.6 percentage points; 95% confidence interval, −6.1 to −1.0; hazard ratio, 0.71; 95% confidence interval, 0.56 to 0.91; \( P < 0.001 \) for non-inferiority and \( P = 0.005 \) for superiority). Furthermore, a polymer-free DES was superior to a BMS with respect to the clinically driven target revascularization (risk difference, −4.8 percentage points; 95% confidence interval, −6.9 to −2.6%; hazard ratio, 0.50; 95% confidence interval, 0.37 to 0.69; \( P < 0.001 \)).

Several years ago, we developed a new BMS (TIGER®), which has high flexibility and a thin stent strut (70 µm). We have evaluated the safety and efficacy of various DESs in both human and animal studies for a long time. More recently, a novel drug-combining method on a stent surface using nitrogen-doped TiO₂ film deposition was developed. Titanium exhibits good biocompatibility and mechanical properties. It is commonly used in...
dental and orthopedic devices. Nan et al.\textsuperscript{30} fabricated a non-stoichiometric TiO\textsubscript{2} film using ion-beam-enhanced deposition. They reported that the blood compatibility of the heat valve materials was improved by TiO\textsubscript{2} film coating. Windecker et al.\textsuperscript{31} reported that titanium-nitride-oxide-coated stents had superior biocompatibility to stainless steel stents in terms of platelet adhesion and fibrinogen binding. In the present study, the TiO\textsubscript{2} film was deposited onto the BMS via a plasma-enhanced chemical vapor deposition process. Its applicability as a drug-coating matrix was demonstrated to be a promising alternative to the polymers of DESs.\textsuperscript{8,9} Moreover, the release rate of everolimus was faster with the use of a polymer-free TiO\textsubscript{2} film than with the conventional PLGA polymer, despite the fact that it was attenuated via the electrospinning coating method. Furthermore, the TIGEREVOLUTION\textsuperscript{®} stent showed comparable results with a commercial durable-polymer everolimus-eluting stent (XIENCE Prime\textsuperscript{®}, Abbott Vascular) with regard to the drug release rate.\textsuperscript{13,32}

We initially assessed the efficacy of a polymer-free DES coated with everolimus using nitrogen-doped TiO\textsubscript{2} film deposition in a porcine coronary restenosis model with a 4-week follow-up.\textsuperscript{13} This preliminary study included four stent groups, including BMS (group I; TIGER\textsuperscript{®}), BMS (TIGER\textsuperscript{®}) with nitrogen-doped TiO\textsubscript{2} film deposition (group II), commercial everolimus-eluting stent (group III; XIENCE Prime\textsuperscript{®}), and polymer-free everolimus-eluting stent using nitrogen-doped TiO\textsubscript{2} film deposition (group IV: TIGEREVOLUTION\textsuperscript{®}). The results showed that the percentage area of stenosis was lower in groups III and IV than in group I (30.2\% \pm 11.7\% vs. 29.2\% \pm 8.9\% vs. 46.4\% \pm 13.8\%, respectively, \(P = 0.005\)). However, the fibrin score was higher in groups III and IV compared to groups I and II (2.27 \pm 0.24 vs. 1.75 \pm 0.31 vs. 0.87 \pm 0.67 vs. 0.76 \pm 0.61, respectively, \(P < 0.001\)). Injury and inflammation scores were not significantly different among the four groups. In the present study, we performed OCT 6 months after stent implantation to accurately compare the percentage area of stenosis between the TIGEREVOLUTION\textsuperscript{®} stent and the XIENCE Alpine\textsuperscript{®} stent in a mini-pig model. The results demonstrated no significant difference in the percentage area of stenosis between the groups, as assessed by OCT. Recently, an investigational new drug application for the TIGEREVOLUTION\textsuperscript{®} stent was approved by the Korean Food and Drug Administration on July 31, 2020. Furthermore, a pilot study of the TIGEREVOLUTION\textsuperscript{®} stent involving 20 humans is being performed in 2021 with the support of the Korea Medical Device Development Fund.

The present study has some limitations. First, an inherent limitation is that the stent was implanted in the normal porcine coronary artery in an oversized manner, which is a scenario different from atherosclerotic coronary restenosis in humans. Second, the selection of the artery to be stented was chosen not based on web-based randomization but on the suitability for implanting the stent by QCA results. Moreover, the limited resources of the animal study were considered. Third, although OCT assessment was performed by two analysts and blinded using anatomical naming, differences in stent platform might affect the results of the analysis.\textsuperscript{33} Furthermore, information on intra- or interobserver variability was not included. Fourth, we did not consider potential confounders such as cholesterol levels, although we controlled for the order of procedures and measurements. Finally, we were unable to verify the cause of death in one pig.

In our preclinical study, the novel polymer-free everolimus-eluting stent using nitrogen-doped TiO\textsubscript{2} film deposition, the TIGEREVOLUTION\textsuperscript{®} stent, had results comparable with those of a commercial durable polymer everolimus-eluting stent, the XIENCE Alpine\textsuperscript{®} stent, in 6-month OCT and histological findings in a mini-pig model.
ACKNOWLEDGMENTS

We wish to thank Jung Hoon Kim, PhD (Chonnam National University Hospital) for his support with the animal experiments.

REFERENCES

1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. *Lancet* 1978;1(8058):263. [PUBMED] [CROSSREF]

2. Torrado J, Buckley L, Durán A, Trujillo P, Toldo S, Valle Raleigh J, et al. Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis. *J Am Coll Cardiol* 2018;71(15):1676-95. [PUBMED] [CROSSREF]

3. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. *Circulation* 2007;115(11):1440-55. [PUBMED] [CROSSREF]

4. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al. Vascular responses to drug eluting stents: importance of delayed healing. *Arterioscler Thromb Vasc Biol* 2007;27(7):1500-40. [PUBMED] [CROSSREF]

5. Yazdani SK, Vorpahl M, Nakano M, Su SH, Kolodgie FD, Virmani R. In vitro and in vivo characterisation of biodegradable polymer-based drug-eluting stent. *EuroIntervention* 2011;7(7):835-43. [PUBMED] [CROSSREF]

6. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Alvarez J, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. *J Am Coll Cardiol* 2006;47(1):175-81. [PUBMED] [CROSSREF]

7. Otsuka Y, Chronos NA, Apkarian RP, Robinson KA. Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. *J Invasive Cardiol* 2007;19(2):71-6. [PUBMED]

8. Song SJ, Park YJ, Park J, Cho MD, Kim JH, Jeong MH, et al. Preparation of a drug-eluting stent using a TiO2 film deposited by plasma enhanced chemical vapour deposition as a drug-combining matrix. *J Mater Chem* 2010;20(23):4792-801. [CROSSREF]

9. Song SJ, Jung KW, Park YJ, Park J, Cho MD, Jeong MH, et al. Nitrogen-doped TiO2 films as drug-binding matrices for the preparation of drug-eluting stents. *J Mater Chem* 2011;21(22):8169-77. [CROSSREF]

10. Lim KS, Bae IH, Kim JH, Park DS, Kim JM, Kim JH, et al. Mechanical and histopathological comparison between commercialized and newly designed coronary bare metal stents in a porcine coronary restenosis model. *Chonnam Med J* 2013;49(1):7-13. [PUBMED] [CROSSREF]

11. Lim KS, Jeong MH, Bae IH, Park JK, Park DS, Kim JM, et al. Effect of polymer-free TiO2 stent coated with abciximab or alpha lipoic acid in porcine coronary restenosis model. *J Cardiol* 2014;64(5):409-18. [PUBMED] [CROSSREF]

12. Bae IH, Lim KS, Park JK, Park DS, Lee SY, Jang EJ, et al. Mechanical behavior and in vivo properties of newly designed bare metal stent for enhanced flexibility. *J Ind Eng Chem* 2015;21:1295-300. [CROSSREF]

13. Sim DS, Jeong MH, Park DS, Kim JH, Lim KS, Bae IH, et al. A novel polymer-free drug-eluting stent coated with everolimus using nitrogen-doped titanium dioxide film deposition in a porcine coronary restenosis model. *Int J Cardiol* 2016;222:436-40. [PUBMED] [CROSSREF]

14. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. *J Am Coll Cardiol* 1992;19(2):265-74. [PUBMED] [CROSSREF]

15. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. *J Am Coll Cardiol* 1998;31(1):224-30. [PUBMED] [CROSSREF]
16. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. *Circulation* 2005;112(2):270-8. 
[PubMed] [CrossRef]

17. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003;349(14):1315-23. 
[PubMed] [CrossRef]

18. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med* 2004;350(3):221-31. 
[PubMed] [CrossRef]

19. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. *J Am Coll Cardiol* 2005;45(12):2088-92. 
[PubMed] [CrossRef]

20. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. *Eur Heart J* 2006;27(23):2784-814. 
[PubMed] [CrossRef]

21. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. *J Am Coll Cardiol* 2006;48(12):2584-91. 
[PubMed] [CrossRef]

22. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. *N Engl J Med* 2007;356(10):1009-19. 
[PubMed] [CrossRef]

23. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2021;42(14):1289-367. 
[PubMed] [CrossRef]

24. Mauler-Wittwer S, Garot P. The Biolimus A9-coated BioFreedom™ stent: from clinical efficacy to real-world evidence. *Future Cardiol* 2021;17(2):239-55. 
[PubMed] [CrossRef]

25. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. *N Engl J Med* 2015;373(21):2038-47. 
[PubMed] [CrossRef]

26. Hong YJ, Jeong MH, Lee SR, Hong SN, Kim KH, Park HW, et al. Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model. *J Korean Med Sci* 2007;22(5):802-9. 
[PubMed] [CrossRef]

27. Cortes C, Chu M, Schincariol M, Martinez-Hervás Alonso MA, Reisbeck B, Zhang R, et al. Identification of the type of stent with three-dimensional optical coherence tomography: the SPQR study. *EuroIntervention* 2021;17(2):e140-8. 
[PubMed] [CrossRef]